{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-279021","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.899351+00:00","generated_at":"2026-05-29T02:56:31.578026+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viridian's veligrotug meets all primary & secondary endpoints in Phase 3 THRIVE-2 chronic TED trial","bullets":["Proptosis responder rate 56% vs 8% placebo (48% adj, p<0.0001); 2.34mm mean reduction vs 0.46mm.","Diplopia response 56% vs 25% (p=0.0006); complete resolution 32% vs 14% (p=0.0152) in chronic patients.","54% of veligrotug patients achieved CAS 0 or 1 vs 24% placebo (p=0.006); overall responder rate 56% vs 7%.","Veligrotug well-tolerated; 94% completed treatment; 9.6% placebo-adjusted rate of hearing impairment.","BLA submission on track for H2 2025; $753M cash on hand provides runway into H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-279021","json":"https://secwatch.observer/filing/0001193125-24-279021.json","markdown":"https://secwatch.observer/filing/0001193125-24-279021.md","text":"https://secwatch.observer/filing/0001193125-24-279021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/0001193125-24-279021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:56:31.578026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}